Vie Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vie data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vie Data Today - Breaking & Trending Today

Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3

Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg. ....

United Kingdom , United States , Jemecg Hidradenitis Suppurativa , Roopal Thakkar , Hidradenitis Suppurativa , Exchange Commission , Journal Of The American Academy Dermatology , Garga Association Between Hidradenitis Suppurativa , Hurley Stage , Treatment Diff , Baseline Hurley Stage About Hidradenitis , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Vie Data , Assess Disease Activity , Subcutaneous Lutikizumab , Adult Participants With Moderate , Rev Clin , Psychological Comorbidities , Impaired Quality , Curr Pain Headache , New England Journal , Between Hidradenitis Suppurativa , American Academy , Accessed December ,

Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3

Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg every other week showed higher response rates in HiSCR 50 at week 16 than those treated. ....

United Kingdom , United States , Hidradenitis Suppurativa , Roopal Thakkar , Jemecg Hidradenitis Suppurativa , Garga Association Between Hidradenitis Suppurativa , Journal Of The American Academy Dermatology , Exchange Commission , Showed Positive Results , Severe Hidradenitis Suppurativa , Program Advances , Hurley Stage , Treatment Diff , Baseline Hurley Stage About Hidradenitis , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Vie Data , Assess Disease Activity , Subcutaneous Lutikizumab , Adult Participants With Moderate , Rev Clin , Psychological Comorbidities , Impaired Quality , Curr Pain Headache , New England Journal ,

AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress

AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Stefan Florentinus , Global Medical Affairs , European Academy Of Dermatology , Abbvie Ltd , Boehringer Ingelheim , Free Communications In Atopic Dermatitis , Improvements In Health , European Union , Free Communications In Psychodermatology , Abbvie Deutschland Gmbh Co , European Commission , Exchange Commission , Maintenance Of Health , Cohort Study Using Clinical Practice Research Datalink , European Academy , Vie Data , Hand Eczema , Moderate To Severe Atopic Dermatitis , Two Phase , Dupilumab Treatment , Severe Atopic Dermatitis , Four Body Regions , Heads Up Study , Oral Presentation , Free Communications , Atopic Dermatitis ,

RINVOQ Achieved Superiority Versus DUPIXENT® For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis

ABBVie today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib achieved superiority to dupilumab for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Area Severity Index at week 16, in adults with moderate to severe atopic dermatitis. 1 Of patients treated with upadacitinib, 71 percent achieved EASI 75 at week 16 compared to 61 …
ABBVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved superiority to dupilumab (300 mg, every other week) for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, in adults with moderate to severe atopic dermatitis. 1 Of patients treated with upadacitinib, 71 percent achieved EASI 75 at week 16 compared to 61 percent of dupilumab-treated patients (p=0.006). 1 Upadacitinib also showed sup ....

United States , Michael Severino , Upadacitinib Monotherapy , European Academy Of Dermatology , European Commission , Drug Administration , Exchange Commission , Abbvie Inc , Venerology Congress , Clinical Program , Eczema Area Severity Index , Worst Pruritus Numerical Rating Scale , Worst Pruritus , Eczema Area , Safety Information , Important Safety Information , Mississippi River , Full Prescribing Information , Medication Guide , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Vie Data , Moderate To Severe Atopic Dermatitis , Results From , Placebo Controlled Studies ,

RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis

RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
- 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1]
- Upadacitinib showed superiority versus dupilumab for all ranked secondary endpoints, including early improvements in itch and skin clearance[1]
- The Heads Up study evaluated upadacitinib (30 mg, once daily) versus dupilumab (300 mg, every other week) in adults with moderate to severe atopic dermatitis[1]
- The safety profile of upadacitinib was consistent with previous atopic dermatitis studies, with no new safety risks observed[1-3] ....

United States , Michael Severino , Upadacitinib Monotherapy , European Academy Of Dermatology , European Commission , Drug Administration , Exchange Commission , Abbvie Inc , Venerology Congress , Clinical Program , Eczema Area Severity Index , Worst Pruritus Numerical Rating Scale , Heads Up Results , Worst Pruritus , About Atopic , Safety Information , Important Safety Information , Mississippi River , Full Prescribing Information , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Vie Data , Moderate To Severe Atopic Dermatitis , Results From , Placebo Controlled Studies ,